- Home
- WDC vs JNJ Comparison
WDC vs JNJ Comparison
Compare WDC & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDC | JNJ |
|---|---|---|
| Founded | 1970 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4B | 542.4B |
| IPO Year | 1999 | 2003 |
Fundamental Metrics
Financial Performance| Metric | WDC | JNJ |
|---|---|---|
| Price | $529.03 | $238.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 20 |
| Target Price | ★ $281.77 | $238.20 |
| AVG Volume (30 Days) | 5.1M | ★ 6.3M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | 0.12% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | ★ 16.05 | 2.14 |
| Revenue | ★ $9,520,000,000.00 | N/A |
| Revenue This Year | $32.24 | $6.63 |
| Revenue Next Year | $26.55 | $7.43 |
| P/E Ratio | ★ $30.53 | $111.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.60 | $149.04 |
| 52 Week High | $602.54 | $251.71 |
Technical Indicators
Market Signals| Indicator | WDC | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 65.86 |
| Support Level | $434.00 | $233.83 |
| Resistance Level | $525.15 | $246.40 |
| Average True Range (ATR) | 31.42 | 4.13 |
| MACD | -7.87 | 1.60 |
| Stochastic Oscillator | 36.83 | 94.87 |
Price Performance
Historical ComparisonAbout WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.